Biomunex Pharmaceuticals has established its U.S. subsidiary, Biomunex Pharmaceuticals Inc., in Cambridge, MA. The opening of this subsidiary is the first step in the company’s strategy to expand Biomunex’ activities in the U.S., with the initial focus on facilitating Research & Development partnerships and business development activities with pharmaceutical companies and leading academic institutions. 
 
“Following our recent licensing agreement with Sanofi for the generation and optimization of bi- and multi-specific antibody therapeutics, we are excited about ramping up our R&D and partnering activities in the United States with the establishment of Biomunex Inc.,” said Dr. Pierre-Emmanuel Gerard. “We are delighted to open our U.S. subsidiary in Cambridge, MA, which probably represents the largest biotech cluster in the world, especially in the therapeutic antibody field. Biomunex’ ambition is to develop its product pipeline globally and this first step paves the way for U.S. developments.”

“The establishment of the U.S. subsidiary will contribute to our global R&D objectives by increasing discovery and development partnerships based on the BiXAb® technology with major U.S. academic and industrial teams. Biomunex Inc. will also accelerate the preclinical and clinical development of our proprietary BiXAb® antibodies,” added Dr. Eugene Zhukovsky.